181 related articles for article (PubMed ID: 11795188)
21. Blood pressure variability and cardiovascular risk in treated hypertensive patients.
Pierdomenico SD; Lapenna D; Di Tommaso R; Di Carlo S; Esposito AL; Di Mascio R; Ballone E; Cuccurullo F; Mezzetti A
Am J Hypertens; 2006 Oct; 19(10):991-7. PubMed ID: 17027816
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity.
Felder RA; Jose PA
Nat Clin Pract Nephrol; 2006 Nov; 2(11):637-50. PubMed ID: 17066056
[TBL] [Abstract][Full Text] [Related]
23. [Aldosterone and cardiovascular diseases, more than water and salt retention].
Duprez D
Verh K Acad Geneeskd Belg; 2002; 64(3):225-32. PubMed ID: 12238244
[TBL] [Abstract][Full Text] [Related]
24. [Drugs and arterial stiffness in hypertensive patients].
Laurent S
Drugs; 2003; 63 Spec No 1():1-8. PubMed ID: 12708878
[TBL] [Abstract][Full Text] [Related]
25. [Salt sensitivity in essential hypertension].
Ando K
Nihon Rinsho; 2000 Jan; 58 Suppl 1():698-702. PubMed ID: 11026362
[No Abstract] [Full Text] [Related]
26. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
27. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
Hermida RC
Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
[TBL] [Abstract][Full Text] [Related]
28. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension.
Tian N; Rose RA; Jordan S; Dwyer TM; Hughson MD; Manning RD
J Hypertens; 2006 Nov; 24(11):2263-70. PubMed ID: 17053549
[TBL] [Abstract][Full Text] [Related]
29. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
30. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
Flaa A; Aksnes TA; Strand A; Kjeldsen SE
Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
[TBL] [Abstract][Full Text] [Related]
31. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
[TBL] [Abstract][Full Text] [Related]
32. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
33. Weak effect of hypertension and other classic risk factors in the elderly who have already paid their toll.
Casiglia E; Mazza A; Tikhonoff V; Pavei A; Privato G; Schenal N; Pessina AC
J Hum Hypertens; 2002 Jan; 16(1):21-31. PubMed ID: 11840226
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiology of antihypertensive therapy with diuretics.
Fukuda M; Kimura G
Hypertens Res; 2006 Sep; 29(9):645-53. PubMed ID: 17249519
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
36. Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension.
de Jongh RT; Serné EH; IJzerman RG; Stehouwer CD
J Hypertens; 2007 Sep; 25(9):1887-93. PubMed ID: 17762653
[TBL] [Abstract][Full Text] [Related]
37. [Arterial hypertension and the kidney].
Niang A
Dakar Med; 2008; 53(1):1-6. PubMed ID: 19102111
[TBL] [Abstract][Full Text] [Related]
38. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension.
Fagard RH; Thijs L; Staessen JA; Clement DL; De Buyzere ML; De Bacquer DA
J Hum Hypertens; 2009 Oct; 23(10):645-53. PubMed ID: 19225527
[TBL] [Abstract][Full Text] [Related]
39. Increased levels of atherosclerosis markers in salt-sensitive hypertension.
Larrousse M; Bragulat E; Segarra M; Sierra C; Coca A; de La Sierra A
Am J Hypertens; 2006 Jan; 19(1):87-93. PubMed ID: 16461197
[TBL] [Abstract][Full Text] [Related]
40. [Value of ambulatory arterial pressure monitoring in the prediction of target-organ damage and cardiovascular events].
Hermida RC; Ayala DE; Calvo C
Nefrologia; 2002; 22 Suppl 3():59-67. PubMed ID: 12014304
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
